Tools
Stock profile

Eton Pharmaceuticals, Inc. (ETON)

ETON · Latest close $61.99 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$61.99
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

Eton Pharmaceuticals, Inc. (ETON) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $10.4M sold). Latest close $61.99 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-10.4M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Polen Capital Management — 1 tracked fund hold ETON. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 12 sales ($10.4M). Insider trading

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Polen Capital Management0.01%45,379ADDED (+50.6%) Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +73.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

68.408.112024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding163 of 8,857 filers
Long-only filers among them163
Change vs 2026 Q1+51 net · 159 entered · 108 exited
Shares reported, all filers19,900,542
Reported value, all filers$714.8M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$80.0M
Net income · FY2025$-4.6M
Total assets · FY2025$92.1M
Shares outstanding28,583,135
Market cap (at latest close)$1.8B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 11, 2026.

Short interest

Shares short · Oct 15, 20261,943,339
Share of shares outstanding6.80%
Days to cover3.30

Shares short at recent settlements — Jul 31, 2026: 1.3M · Aug 14, 2026: 1.4M · Aug 31, 2026: 1.3M · Sep 15, 2026: 1.5M · Sep 30, 2026: 1.8M · Oct 15, 2026: 1.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 11, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 11, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 12 sales by 4 insiders ($10.4M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 10, 2026Erdogan-Trinkaus IpekChief Commercial OfficerSell2,340$67.18$157.2KSEC filing
Nov 10, 2026Erdogan-Trinkaus IpekChief Commercial OfficerSell1,160$67.88$78.7KSEC filing
Nov 10, 2026CASAMENTO CHARLES JSell6,380$64.33$410.4KSEC filing
Nov 10, 2026CASAMENTO CHARLES JSell14,715$65.32$961.3KSEC filing
Nov 10, 2026CASAMENTO CHARLES JSell22,601$66.26$1.5MSEC filing
Nov 10, 2026CASAMENTO CHARLES JSell33,956$67.11$2.3MSEC filing
Nov 10, 2026CASAMENTO CHARLES JSell2,903$67.87$197.0KSEC filing
Oct 6, 2026Krempa DavidChief Business OfficerSell4,166$55.07$229.4KSEC filing
Aug 28, 2026MAIER PAUL VSell36,387$58.64$2.1MSEC filing
Aug 28, 2026MAIER PAUL VSell13,485$60.21$811.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 6, 2026Krempa DavidOfficer4,166$229.4KOct 6, 2026SEC filing
Aug 28, 2026MAIER PAUL VDirector50,000$3.0MAug 28, 2026SEC filing
Aug 24, 2026Krempa DavidOfficer25,000$1.6MAug 24, 2026SEC filing
Aug 20, 2026BRYNJELSEN SEANOfficer, Director100,000$6.3MAug 19, 2026SEC filing
Aug 19, 2026BRYNJELSEN SEANDirector, 10% Stockholder100,000$6.3MAug 19, 2026SEC filing
Jun 26, 2026Gruber James R.Officer251,818$9.0MJun 26, 2026SEC filing
Jun 25, 2026Gruber James R.Officer25,000$875.3KJun 25, 2026SEC filing
Jun 23, 2026Gruber James R.Officer25,000$830.9KJun 23, 2026SEC filing
Jun 17, 2026Adams Jennifer McKieDirector50,000$1.6MJun 17, 2026SEC filing
Jun 2, 2026Gruber James R.Officer3,117$84.2KJun 2, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 28, 2026BlackRock, Inc.SC 13G/A1,882,4106.9%Jun 30, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Oct 30, 2025The Vanguard GroupSC 13G1,344,1155.0%Sep 30, 2025SEC filing
Jul 17, 2025BlackRock, Inc.SC 13G1,530,3575.7%Jun 30, 2025SEC filing
Feb 14, 2025EcoR1 Capital, LLCSC 13G/A1,981,0037.7%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Financial Screens

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Gross Profitability (Novy-Marx) — Gross profit / assets: 46.4% · Gross margin: 53.5%

· Distress Risk (Altman Z″) — Z″-Score: -2.05 · Working capital / assets: 0.24 · Retained earnings / assets: -1.22 · EBIT / assets: -0.01 · Equity / liabilities: 0.40

· Auditor Change (8-K 4.01) — Latest event: Jun 20, 2025 · Events in 2 yrs: 1

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold ETON — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Nov 5, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Nov 2, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on ETON

One email a week: the week’s new filings and research. Subscribe free

← ETN  ·  ETOR →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.